Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.38 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1830615 | 0.84 | PDE10A (0.37) | PDE10ATDP1PDK2PDK4LMNA | |
| SCHEMBL24538435 | 0.80 | PDE10A (0.34) | PDE10ATDP1PDK2 | |
| SCHEMBL10813311 | 0.80 | PDE10A (0.34) | PDE10ATDP1PDK2 | |
| SCHEMBL259072 | 0.80 | PDE10A (0.52) | PDE10ATDP1PDK2ALDH1A1LMNA | |
| SCHEMBL4256550 | 0.78 | USP2 (0.35) | PDE10APDK2ALDH1A1 | |
| SCHEMBL11916226 | 0.76 | CYP2C19 (0.42) | PDE10ATDP1PDK2ALDH1A1LMNA | |
| SCHEMBL12303154 | 0.76 | PDK2 (0.36) | PDE10APDK2PDK4 | |
| SCHEMBL19773336 | 0.74 | PDK2 (0.37) | PDE10APDK2ALDH1A1 | |
| SCHEMBL112929 | 0.73 | HTT (0.46) | PDE10ATDP1PDK2PDK4ALDH1A1 | |
| SCHEMBL8055181 | 0.73 | TDP1 (0.35) | TDP1PDK2PDK4ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12479857-B2 | Bax inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-07-17 | — | — | US | disclosed |
| EP-3558310-B1 | HETEROARYL PIPERIDINE ETHER ALLOSTERIC MODULATORS OF THE M4 MUSCARINIC ACETYLCHOLINE RECEPTOR | MERCK SHARP & DOHME LLC (US) | 2024-01-17 | — | — | EP | disclosed |
| US-11858915-B2 | Polo like kinase 4 inhibitors | ORIC PHARMACEUTICALS, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| WO-2023117724-A1 | ISOTHIOCYANATOETHYNYLBENZENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023064585-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023064585-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIVERSITY | 2022-12-08 | — | — | US | disclosed |
| US-6756367-B2 | USEFUL IN THE TREATMENT OF ANY STATE WITH INCREASED ENDOGENOUS LEVEL OF CORTICOTROPIN RELEASING HORMONE(CRF) OR HPA (HYPOTHALAMIC PITUITARY AXIS) IS DISREGULATED OR DISEASES INDUCED BY CRF, INCLUDING INFLAMMATORY DISORDERS, ANXIETY ETC | NOVARTIS AG (CH) | 2004-06-29 | — | — | US | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004048375-A1 | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, METHOD FOR PREPARING SAME, USE THEREOF AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | PROSKELIA SAS (FR) | 2004-06-10 | — | — | WO | disclosed |
| EP-0764166-B1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER (US) | 2000-09-13 | — | — | EP | disclosed |
| US-5962479-A | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0764166-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1997-03-26 | — | — | EP | disclosed |
| WO-1995033750-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER INC. (US) | 1995-12-14 | — | — | WO | disclosed |
| EP-0210025-A2 | 5-Substituted-6-aminopyrimidine derivatives, composition and uses | AMERICAN HOME PRODUCTS CORPORATION (US) | 1987-01-28 | — | — | EP | disclosed |
| US-4617393-A | CONGESITIVE HEART FAILURE | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-10-14 | — | — | US | disclosed |
| US-3974166-A | FUNGICIDE | CIBA-GEIGY CORPORATION (US) | 1976-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | PDE10A 4243/4885TDP1 1525/4885PDK2 3082/4885 |
| US-11858915-B2 | Polo like kinase 4 inhibitors | PLK4, PLK2, PLK3 | PDE10A 2023/4885TDP1 659/4885PDK2 92/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | PDE10A 3096/4885TDP1 475/4885PDK2 171/4885 |
| US-20220389028-A1 | BAX INHIBITORS AND USES THEREOF | BAX, TMBIM6, BCL2 | PDE10A 3700/4885TDP1 1551/4885PDK2 846/4885 |
| US-12479857-B2 | Bax inhibitors and uses thereof | BAX, TMBIM6, BCL2 | PDE10A 3700/4885TDP1 1551/4885PDK2 846/4885 |
| US-20250230155-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | PDE10A 1498/4885TDP1 1645/4885PDK2 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.